Advanced

Erlotinib accumulation in brain metastases from non-small cell lung cancer : visualization by positron emission tomography in a patient harboring a mutation in the epidermal growth factor receptor

Weber, Britta ; Winterdahl, Michael ; Memon, Ashfaque LU ; Sorensen, Boe S ; Keiding, Susanne ; Sorensen, Leif ; Nexo, Ebba and Meldgaard, Peter (2011) In Journal of Thoracic Oncology 6(7). p.9-1287
Abstract

INTRODUCTION: Drugs directed toward the epidermal growth factor receptor (EGFR), such as erlotinib (Tarceva®) and gefitinib (Iressa®), are used for the treatment of patients with advanced non-small cell lung cancer (NSCLC), including patients with brain metastases. However, whether erlotinib actually enters into brain metastases has not been adequately elucidated. In this study, we investigated the accumulation of [¹¹C]-erlotinib by positron emission tomography (PET) combined with computed tomography (CT) and magnetic resonance imaging (MRI).

METHODS: A 32-year-old patient with NSCLC and multiple brain metastases was treated with first-line erlotinib. EGFR mutations were determined by analyzing a fine-needle lung tumor biopsy... (More)

INTRODUCTION: Drugs directed toward the epidermal growth factor receptor (EGFR), such as erlotinib (Tarceva®) and gefitinib (Iressa®), are used for the treatment of patients with advanced non-small cell lung cancer (NSCLC), including patients with brain metastases. However, whether erlotinib actually enters into brain metastases has not been adequately elucidated. In this study, we investigated the accumulation of [¹¹C]-erlotinib by positron emission tomography (PET) combined with computed tomography (CT) and magnetic resonance imaging (MRI).

METHODS: A 32-year-old patient with NSCLC and multiple brain metastases was treated with first-line erlotinib. EGFR mutations were determined by analyzing a fine-needle lung tumor biopsy taken before the treatment. A PET/CT of the brain with [¹¹C]-erlotinib was performed during treatment, and a MRI of the head and a CT of the chest were performed pre- and posttreatment.

RESULTS: The primary lung tumor displayed an erlotinib-sensitizing exon 19 deletion in the EGFR gene, and [¹¹C]-erlotinib PET/CT showed accumulation in the brain metastases. Posttreatment MRI and CT demonstrated regression of both brain metastases and primary lung tumor.

CONCLUSION: Our data demonstrated that erlotinib accumulated in brain metastases in a NSCLC patient who responded to the treatment.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; and
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Adult, Brain Neoplasms/diagnostic imaging, Carcinoma, Non-Small-Cell Lung/diagnostic imaging, Drug Resistance, Neoplasm/genetics, ErbB Receptors/genetics, Erlotinib Hydrochloride, Female, Humans, Lung Neoplasms/diagnostic imaging, Mutation/genetics, Neoplasm Staging, Positron-Emission Tomography, Prognosis, Protein Kinase Inhibitors/pharmacology, Quinazolines/pharmacology, Survival Rate, Tomography, X-Ray Computed
in
Journal of Thoracic Oncology
volume
6
issue
7
pages
3 pages
publisher
Elsevier
external identifiers
  • scopus:79959914514
  • pmid:21847041
ISSN
1556-1380
DOI
10.1097/JTO.0b013e318219ab87
language
English
LU publication?
no
id
4623bdad-eba4-4d57-a916-6b9112ddf1a1
date added to LUP
2019-11-22 16:17:22
date last changed
2020-09-23 08:00:38
@misc{4623bdad-eba4-4d57-a916-6b9112ddf1a1,
  abstract     = {<p>INTRODUCTION: Drugs directed toward the epidermal growth factor receptor (EGFR), such as erlotinib (Tarceva®) and gefitinib (Iressa®), are used for the treatment of patients with advanced non-small cell lung cancer (NSCLC), including patients with brain metastases. However, whether erlotinib actually enters into brain metastases has not been adequately elucidated. In this study, we investigated the accumulation of [¹¹C]-erlotinib by positron emission tomography (PET) combined with computed tomography (CT) and magnetic resonance imaging (MRI).</p><p>METHODS: A 32-year-old patient with NSCLC and multiple brain metastases was treated with first-line erlotinib. EGFR mutations were determined by analyzing a fine-needle lung tumor biopsy taken before the treatment. A PET/CT of the brain with [¹¹C]-erlotinib was performed during treatment, and a MRI of the head and a CT of the chest were performed pre- and posttreatment.</p><p>RESULTS: The primary lung tumor displayed an erlotinib-sensitizing exon 19 deletion in the EGFR gene, and [¹¹C]-erlotinib PET/CT showed accumulation in the brain metastases. Posttreatment MRI and CT demonstrated regression of both brain metastases and primary lung tumor.</p><p>CONCLUSION: Our data demonstrated that erlotinib accumulated in brain metastases in a NSCLC patient who responded to the treatment.</p>},
  author       = {Weber, Britta and Winterdahl, Michael and Memon, Ashfaque and Sorensen, Boe S and Keiding, Susanne and Sorensen, Leif and Nexo, Ebba and Meldgaard, Peter},
  issn         = {1556-1380},
  language     = {eng},
  number       = {7},
  pages        = {9--1287},
  publisher    = {Elsevier},
  series       = {Journal of Thoracic Oncology},
  title        = {Erlotinib accumulation in brain metastases from non-small cell lung cancer : visualization by positron emission tomography in a patient harboring a mutation in the epidermal growth factor receptor},
  url          = {http://dx.doi.org/10.1097/JTO.0b013e318219ab87},
  doi          = {10.1097/JTO.0b013e318219ab87},
  volume       = {6},
  year         = {2011},
}